Total costs of Kymriah and the 21 similar drugs in development — known as CAR T-cell therapies — will be far higher than many have imagined, reaching $1 million or more per patient, according to leading cancer experts. The next CAR T-cell drug could be approved as soon as November.

Quick Read

In a deal similar to the one that turned the tide against AIDS, manufacturers and charities will make chemotherapy drugs available in six poor countries at steep discounts

Quick Read

There are currently 96,559 candidates on the list awaiting a kidney transplant in the US. In major cities, the average wait is five to ten years. For those on the list, there are meager options to get off it. They could receive a kidney donation from a relative or a friend. Internationally, some have opted for a murkier route

Quick Read

If developed and used sensitively, artificial intelligence systems could go a long way to mitigating these inequalities by removing human bias. A careless approach, however, could make the situation worse

Quick Read

Poor and minority patients receive less optimal pain management, are placed on enhanced recovery protocols later than wealthier, white counterparts

Quick Read

Who Gets Health in Old Age?

September 20, 2017

Rich, White People. Access to insurance isn’t erasing race- and class-based health disparities

Quick Read

In April, Gundy’s child, who is on private insurance, began getting the drug Spinraza, which costs $750,000 for the initial year of treatment. Chaffin’s child — a Medicaid enrollee — was not receiving the drug, as his state regulators debated whether to offer it to children like him who use ventilators to breathe

Quick Read

Imagine now, that in the future, being poor also meant you were more likely than others to suffer from major genetic disorders like cystic fibrosis, Tay–Sachs disease, and muscular dystrophy. That is a future, some experts fear, that may not be all that far off

Quick Read